Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A N SerafiniK A Harrison

Abstract

To evaluate the effectiveness and safety of samarium-153 (153Sm) lexidronam (EDTMP) in a double-blind, placebo-controlled study. Patients with painful bone metastases secondary to a variety of primary malignancies were randomized to receive 153Sm-EDTMP 0.5 or 1.0 mCi/kg, or placebo. Treatment was unblinded for patients who did not respond by week 4, with those who had received placebo eligible to receive 1.0 mCi/kg of active drug in an open-label manner. Patient and physician evaluations were used to assess pain relief, as was concurrent change in opioid analgesia. One hundred eighteen patients were enrolled onto the study. Patients who received 1.0 mCi/kg of active drug had significant reductions in pain during each of the first 4 weeks in both patient-rated and physician-rated evaluations. Pain relief was observed in 62% to 72% of those who received the 1.O-mCi/kg dose during the first 4 weeks, with marked or complete relief noted in 31% by week 4. Persistence of pain relief was seen through week 16 in 43% of patients who received 1.0 mCi/kg, of active drug. A significant correlation (P = .01) was observed between reductions in opioid analgesic use and pain scores only for those patients who received 1.0 mCi/kg 153Sm-EDTMP. B...Continue Reading

Citations

Mar 8, 2000·The Oncologist·G AuclercD Khayat
Oct 31, 2002·Palliative Medicine·P Good, B Stafford
Aug 2, 2003·Journal of the American Geriatrics Society·Cynthia T McMurtry, James M McMurtry
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Holger PalmedoHans-Jurgen Biersack
Oct 29, 2003·Breast Cancer Research : BCR·Joanne E Mortimer, Marie E Taylor
Oct 13, 2004·The Oncologist·David LussierRussell K Portenoy
Apr 7, 2004·Current Oncology Reports·Michael J MorrisHoward I Scher
May 5, 2005·Current Urology Reports·Michael J MorrisHoward I Scher
Jan 24, 2007·European Journal of Nuclear Medicine and Molecular Imaging·L StrigariC L Maini
Nov 21, 2007·Expert Review of Anticancer Therapy·Pete Anderson, Rodolfo Nuñez
Aug 8, 2009·AJNR. American Journal of Neuroradiology·J J CuaronA E Hirsch
Mar 18, 2010·Nature Reviews. Clinical Oncology·Dirk RadesJanet L Abrahm
Jul 8, 2011·Current Opinion in Supportive and Palliative Care·Daniel J BourgeoisOliver Sartor
Mar 1, 2012·Current Urology Reports·Aurelius Omlin, Johann S de Bono
Mar 29, 2012·Current Opinion in Urology·Brian Lewis, Oliver Sartor
May 15, 2013·The Journal of Urology·Michael S CooksonAdam S Kibel
Mar 29, 2014·Minimally Invasive Surgery·Meena BediSean Tutton
Jul 30, 2014·World Journal of Radiology·Hinrich A WiederKen Herrmann
Jan 4, 2015·Expert Review of Anticancer Therapy·Urbano Anido HerranzLuis Miguel Antón Aparicio
Jul 15, 2015·Therapeutic Advances in Urology·Jim N Rose, Juanita M Crook
Jul 3, 2015·Therapeutic Advances in Medical Oncology·Shobha C SilvaPenella J Woll
Mar 24, 2017·The Cochrane Database of Systematic Reviews·Marta Roqué I FigulsPablo Alonso-Coello
Jun 27, 2018·Nuclear Medicine and Molecular Imaging·Joon Young Choi
Jan 22, 2019·Journal of Labelled Compounds & Radiopharmaceuticals·K V VimalnathSudipta Chakraborty
Mar 22, 2019·Cancers·Ewa SierkoMarek Z Wojtukiewicz
Apr 11, 2020·Cancer Management and Research·Yao ZhuUNKNOWN Expert Group
Sep 22, 2000·Current Review of Pain·C Ripamonti, F Fulfaro
Mar 13, 2002·Drugs & Aging·R C PelgerN A Hamdy
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O IsraelD Front
Oct 2, 2001·Cancer Investigation·M E CooleyE Giarelli
Feb 16, 2002·Scandinavian Journal of Rheumatology·T R MikulsK G Saag
Jun 14, 2000·Cancer Biotherapy & Radiopharmaceuticals·G L DeNardo
Jun 18, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·María Velasco LatrásAmaya Echevarría Icaza
Apr 17, 2003·The Oncologist·Michael J Morris, Howard I Scher
May 19, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Joan Carles GalceránAtika Girard
Jan 2, 2003·Journal of the National Cancer Institute·Gisèle Chvetzoff, Ian F Tannock
Aug 14, 2003·British Journal of Cancer·K LiepeJ Kotzerke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica
K WeissHelmut Sinzinger
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Carla RipamontiEmilio Bombardieri
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Shi-Ming TuChristopher J Logothetis
© 2022 Meta ULC. All rights reserved